Market Access
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Podcast: Identifying The 80% Of Undiagnosed And Misdiagnosed Patients
Vibhor Gupta, director and founder of Pangaea Data, talks to In Vivo about the value of identifying the 80% of patients with undiagnosed or misdiagnosed conditions, and how his company is addressing this need.
COVID To GLP-1: Catalent Plants Ride With Novo To Next Public Health Crisis
A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.
FTC’s Salvos Against Biopharma To Reverberate Through 2024
The Federal Trade Commission broke new ground last year in its opposition to M&A transactions and challenge of Orange Book patent listings. The biopharma community is waiting to see if deals will face similar hurdles in 2024 and whether there will be legal battles if manufacturers of drug-device combination products decline to delist their patents. Researchers advocate that the FTC extend its inquiry to device patents on GLP-1 receptor agonists, including Wegovy and Ozempic.
2024 Radar: UK Medtechs Up The Pace On Sustainability And Assess AI Potential
Three UK medtech companies’ views on how their businesses will be influenced by external factors in the coming year.
Times Of Unprecedented Change: German Medtech Readies For Challenging 2024
German medtech and health care are going through a period of unprecedented change and modernization, with hospital reform on the agenda and integration of digitized functionality happening across the sector. The EU Medical Device Regulation casts a long shadow over the medtech industry and will result in a shake out among companies and products, as In Vivo learnt at Medica 2023.
Why Did The European Commission Decide All Antimicrobials Should Be Rx-Only?
The European Commission responds to questions regarding its decision to include OTC antivirals and antifungals, including commonly used products like thrush and cold sore creams, in the expanded prescription-only requirements for antimicrobials, as part of proposed measures to combat antimicrobial resistance.
Japan’s CEA Scheme: How It Works And Impact So Far
Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?
Moving The Needle In Rare Disease: UCB’s gMG Strategy
Launching a novel drug into a new market is tough. UCB’s Kimberly Moran, talked to In Vivo about how being both patient and digital first gives the company a competitive commercial advantage in an increasingly growing market.
Will Medicare Price Negotiation Stop Post-Approval R&D?
Infographic: One of the more prominent arguments against the Medicare drug price negotiation program is that by limiting the number of years that products can be marketed before price caps are imposed, the scheme discourages development of additional indications.
Medicare Price Setting And The Value Of Post-Approval R&D Spending
Will scrutiny by the Centers for Medicare and Medicaid Services eventually lead to shifts in investment away from improving older drugs toward developing new products?
Manufacturing Devices In The Rollercoaster UK Market
A scale-up strategy is the missing link in the UK devices industry, claims business research organization CPI. Own brand and contract medical manufacturer and packaging company Pennine Healthcare and longstanding medical device CDMO Renfrew Group International give their take on the environment for manufacturers and the opportunities for strengthening the industry base.
Latin America And Caribbean Move Towards Creating A New Regional Regulator
Industry support for a new regional regulator for Latin America and the Caribbean is cautious and experts warn that it could harm competitiveness of the region.
Industry CEOs Talk Drug Pricing, Value And The IRA
Value-based pricing for drugs remains largely a pipe dream in the US, industry leaders say, even as drug pricing pressure mounts.
Innovation Adoption: ‘Medtech’s Ongoing Challenge Of The Day’
UK ministers are increasingly focusing on the need to improve uptake of new technologies in the National Health Service. Ambitious programs have been launched but implementing them effectively for lasting change in a delivery system under acute stress is a challenge of a different order.
China: Value-Based Procurement Reshapes Strategies Of Multinational Medtech Firms
China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.
Physician Behavioral Inertia: Innovation’s Greatest Enemy
Overcoming Inertia is a challenge. Physicians want novel and better medications and products, but evaluating and trying new products takes time and may involve risk.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.